CLINICAL_TRIALS
trial_result
· 2025-02-28
Clinical Trial Update: The Study Observes Afatinib as First-line Treatment in Patients With Epidermal Growth Factor Receptor (EGFR) Mutation-positive Advanced Non-small Cell Lung Cancer
Summary
The study reports results for using afatinib as first-line therapy in patients with EGFR mutation-positive, advanced non-small cell lung cancer.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Boehringer Ingelheim | Conditions: Non-squamous, Non-Small Cell Lung Cancer | Status: COMPLETED | Results posted: 2025-02-28